- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-4-4-mer
- Ligands
- 8 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.2: 11 residues within 4Å:- Chain A: K.769, N.775, S.777, Q.778
- Chain H: S.55, T.56, Y.57, R.58
- Chain K: R.28, L.75, E.76
1 PLIP interactions:1 interactions with chain K- Hydrogen bonds: K:R.28, K:R.28, K:R.28, K:R.28, K:R.28
NAG-NAG-BMA-MAN-MAN.12: 10 residues within 4Å:- Chain B: N.775, S.777, Q.778
- Chain D: S.55, T.56, Y.57, R.58
- Chain G: R.28, L.75, E.76
1 PLIP interactions:1 interactions with chain G- Hydrogen bonds: G:R.28, G:R.28, G:R.28, G:R.28, G:R.28
- 2 x NAG- NAG- BMA- MAN- MAN- MAN- BMA- BMA: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-BMA-BMA.3: 24 residues within 4Å:- Chain A: N.691, F.692, T.693, L.896, N.899, Q.900, Q.1045
- Chain I: G.93, Y.94
- Chain K: A.31, H.32, T.33, S.52, T.53, S.54, T.56, Y.57, K.99, G.100, L.104, S.105, D.106, N.107, D.108
10 PLIP interactions:2 interactions with chain A, 1 interactions with chain I, 7 interactions with chain K- Hydrophobic interactions: A:L.896, A:Q.900
- Hydrogen bonds: I:Y.94, K:T.33, K:T.33, K:T.33, K:K.99, K:S.105, K:D.108, K:D.108
NAG-NAG-BMA-MAN-MAN-MAN-BMA-BMA.13: 24 residues within 4Å:- Chain B: N.691, F.692, T.693, L.896, N.899, Q.900, Q.1045
- Chain E: G.93, Y.94
- Chain G: A.31, H.32, T.33, S.52, T.53, S.54, T.56, Y.57, K.99, G.100, L.104, S.105, D.106, N.107, D.108
10 PLIP interactions:2 interactions with chain B, 1 interactions with chain E, 7 interactions with chain G- Hydrophobic interactions: B:L.896, B:Q.900
- Hydrogen bonds: E:Y.94, G:T.33, G:T.33, G:T.33, G:K.99, G:S.105, G:D.108, G:D.108
- 2 x NAG- NAG- BMA- MAN- BMA: alpha-D-mannopyranose-(1-3)-[beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-BMA.5: 8 residues within 4Å:- Chain A: N.683, I.1104
- Chain B: I.768, D.770
- Chain D: T.33, T.53, D.106
- Chain F: Y.94
3 PLIP interactions:3 interactions with chain D- Hydrogen bonds: D:T.33, D:T.33, D:T.53
NAG-NAG-BMA-MAN-BMA.10: 10 residues within 4Å:- Chain A: I.768, D.770
- Chain C: N.683, I.1104, G.1105
- Chain H: T.33, T.53, S.105, D.106
- Chain J: Y.94
1 PLIP interactions:1 interactions with chain H- Hydrogen bonds: H:D.106
- 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
NAG.15: 2 residues within 4Å:- Chain A: S.34, N.35
Ligand excluded by PLIPNAG.16: 4 residues within 4Å:- Chain A: P.304, N.305, P.553, Q.554
Ligand excluded by PLIPNAG.17: 7 residues within 4Å:- Chain A: F.312, G.313, F.316, N.317, V.341, L.342, F.348
Ligand excluded by PLIPNAG.18: 1 residues within 4Å:- Chain A: N.577
Ligand excluded by PLIPNAG.19: 5 residues within 4Å:- Chain A: A.680, E.1046, K.1047, N.1048
- Chain B: Q.869
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: H.629, N.631
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain A: N.254, E.255, N.256
Ligand excluded by PLIPNAG.22: 3 residues within 4Å:- Chain A: N.590, C.591, T.592
Ligand excluded by PLIPNAG.23: 2 residues within 4Å:- Chain B: S.34, N.35
Ligand excluded by PLIPNAG.24: 4 residues within 4Å:- Chain B: P.304, N.305, P.553, Q.554
Ligand excluded by PLIPNAG.25: 7 residues within 4Å:- Chain B: F.312, G.313, F.316, N.317, V.341, L.342, F.348
Ligand excluded by PLIPNAG.26: 1 residues within 4Å:- Chain B: N.577
Ligand excluded by PLIPNAG.27: 5 residues within 4Å:- Chain B: A.680, E.1046, K.1047, N.1048
- Chain C: Q.869
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain B: H.629, N.631
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain B: N.254, E.255, N.256
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain B: N.590, C.591, T.592
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain B: N.683, N.684
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain C: H.629, V.630, N.631
Ligand excluded by PLIPNAG.33: 5 residues within 4Å:- Chain A: Q.869
- Chain C: A.680, E.1046, K.1047, N.1048
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain C: S.34, N.35
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain C: N.254, E.255, N.256
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain C: P.304, N.305, P.553, Q.554, T.555
Ligand excluded by PLIPNAG.37: 7 residues within 4Å:- Chain C: F.312, G.313, F.316, N.317, V.341, L.342, F.348
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain C: N.577
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain C: N.590, T.592, Q.618
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Williams, W.B. et al., Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell (2021)
- Release Date
- 2020-12-30
- Peptides
- Spike glycoprotein: ABC
2G12 heavy chain: DGHK
2G12 light chain: EFIJ - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DG
GH
HK
ME
EF
FI
KJ
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-4-4-mer
- Ligands
- 8 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN- MAN- MAN- BMA- BMA: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)-[beta-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN- BMA: alpha-D-mannopyranose-(1-3)-[beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Williams, W.B. et al., Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell (2021)
- Release Date
- 2020-12-30
- Peptides
- Spike glycoprotein: ABC
2G12 heavy chain: DGHK
2G12 light chain: EFIJ - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DG
GH
HK
ME
EF
FI
KJ
L